Anlon Healthcare AGM 2026: ₹1,533 Cr Share-Swap Vote

What the company put to shareholders

Anlon Healthcare Limited has scheduled its 13th Annual General Meeting (AGM) for September 5, 2026, with a key resolution tied to a large preferential allotment for consideration other than cash. The company has said the proposed transaction is aimed at making Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL) wholly owned subsidiaries after completion. The AGM is set to be held via video conference at 11:00 am (IST). Alongside the acquisition-related resolution, shareholders will also vote on capital and board-related items.

Corrigendum after exchange observations

On August 25, 2026, Anlon Healthcare informed the exchange that it had issued a corrigendum to the AGM notice. The corrigendum was issued to address observations raised by the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on preferential issue details. The company’s communications indicate that the overall structure of the proposed preferential issue remains focused on the acquisition via share swap. Anlon Healthcare has also disclosed that it corrected the acquisition stake percentages to 44.94% for AOPL and 47.41% for BLPL.

Acquisition structure: preferential allotment through a share swap

The main AGM resolution seeks approval for issuance and allotment of equity shares on a preferential basis for acquiring shares in AOPL and BLPL. The company proposes to acquire up to 44.94% in Apiqo Organics and up to 47.41% in Bizotic Lifescience, which it has stated will result in both entities becoming wholly owned subsidiaries upon completion. The mechanism is a share swap, which means there is no cash consideration involved. The transaction is presented as a preferential allotment for consideration other than cash.

Size of the proposed issue and pricing

Anlon Healthcare has disclosed that it proposes to issue up to 8,58,83,617 fully paid-up equity shares. The equity shares carry a face value of ₹2 each and are proposed to be issued at ₹17.85 per share, including a security premium of ₹15.85. In its AGM-related communication, the company has referred to the proposal as a ₹1,533 crore consideration transaction across the AOPL and BLPL components. The floor price for the issue was stated at ₹17.78 per equity share, determined under SEBI ICDR Regulations using the 90-trading-day volume-weighted average price (VWAP) on NSE preceding August 6, 2026. The company also referred to a valuation report from an independent registered valuer, CA Gaurang Agarwal, to support the price.

Entity-wise allotment and exchange ratios

For AOPL, the company disclosed that 45,16,200 shares of AOPL are proposed to be swapped for 6,52,76,283 Anlon Healthcare shares at ₹17.85 per share. For BLPL, 22,99,000 shares are proposed to be swapped for 2,06,07,334 Anlon Healthcare shares at ₹17.85 per share. The share exchange ratio disclosed is 1:14.45 for AOPL shareholders and 1:8.96 for BLPL shareholders. The company’s corrigendum and subsequent clarifications state that the revisions to stake percentages do not alter the aggregate consideration or exchange ratios.

Promoter participation disclosed in the notice

The AGM documents also list promoter subscriptions in the preferential issue. Chairman and Managing Director Punitkumar Rameshbhai Rasadia is disclosed as subscribing to 1,84,19,402 shares. Whole Time Director Meet Atulkumar Vachhani is disclosed as subscribing to 93,51,099 shares. The company has stated that promoter status for both will remain unchanged post-issue, and that other proposed allottees are listed as non-promoters both currently and post-issue.

Capital and governance agenda at the AGM

Beyond the acquisition-related resolution, Anlon Healthcare is seeking shareholder approval to enhance its authorised share capital from ₹110 crore to ₹130 crore. The proposal includes creating 10 crore additional equity shares, as disclosed in the AGM-related notes. The AGM agenda also includes director-related items, including the reappointment of Punitkumar Rasadia (retiring by rotation) and the appointment of Kishan Vinodkumar Raja as an Independent Director.

Key dates, identifiers, and market snapshot

The exchange filings and meeting calendar point to a tight sequence of events around the AGM notice and corrigendum. The company’s scrip identifiers include BSE: 544497 and NSE: AHCL (Series: EQ), ISIN: INE0Y8W01025. As per the provided market snapshot, Anlon Healthcare’s share price was ₹15.69 on NSE and ₹15.65 on BSE as on September 4, 2026.

Why this matters for shareholders

The AGM vote matters because it bundles a large equity issuance with an acquisition outcome the company has framed as leading to wholly owned subsidiaries. The preferential allotment structure and the disclosed exchange ratios will be central to shareholder evaluation of dilution versus the strategic value of bringing AOPL and BLPL under full control. Separately, the authorised capital increase from ₹110 crore to ₹130 crore is a prerequisite that supports a larger equity base. Director appointments and reappointments also form part of the governance decisions being placed before shareholders.

What happens next

Anlon Healthcare has scheduled the shareholder vote for September 5, 2026, and has already issued a corrigendum to the AGM notice to address BSE and NSE observations on the preferential issue disclosures. The next confirmed step is the AGM outcome, including whether shareholders approve the preferential allotment for the share-swap acquisitions, the authorised capital increase, and the board-related resolutions.